OLX703A / OliX Pharma - LARVOL DELTA

OliX Pharmaceuticals to Participate in BIO Partnering at JPM and Biotech Showcase 2022 Conferences (GlobeNewswire) - "OliX Pharmaceuticals, Inc...announced that the Company’s management will hold one-on-one meetings at BIO Partnering at JPM from January 10-14, 2022. The Company’s management will also participate in Biotech Showcase 2022, being held virtually from January 10-12, 2022 and January 17-19, 2022. Dong Ki Lee, Ph.D., Founder and Chief Executive Officer, Sun Woo Hong, Ph.D., Head of Research and Development, and June Park, Principal Scientist, will be available to discuss platform-based early discovery collaborations and licensing options for its RNAi therapeutic candidates, including OLX703A for hepatitis B..."

Clinical • Hepatitis B • Infectious Disease

OliX Pharmaceuticals to Conduct One-on-One Meetings at BIO-Europe Digital 2021 Conference (GlobeNewswire) - "OliX Pharmaceuticals, Inc...today announced that the Company’s management will hold one-on-one partnering meetings at BIO-Europe Digital 2021, being held virtually October 25-28, 2021. Sun Woo Hong, Ph.D., head of R&D at OliX Pharmaceuticals, and June Hyun Park, Ph.D., principal scientist at OliX Pharmaceuticals, will be available to discuss platform-based early discovery collaborations as well as global licensing options for the Company’s pipeline programs for OLX703A for hepatitis B virus (HBV)..."

Licensing / partnership • Hepatitis B • Infectious Disease